Reblozyl

Product manufactured by Celgene

Application Nr Approved Date Route Status External Links
BLA761136 None Subcutaneous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Reblozyl Is An Erythroid Maturation Agent Indicated For The Treatment Of: Anemia In Adult Patients With Beta Thalassemia Who Require Regular Red Blood Cell (Rbc) Transfusions ( 1.1 ). Anemia Failing An Erythropoiesis Stimulating Agent And Requiring 2 Or More Rbc Units Over 8 Weeks In Adult Patients With Very Low- To Intermediate-Risk Myelodysplastic Syndromes With Ring Sideroblasts (Mds-Rs) Or With Myelodysplastic/myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis (Mds/mpn-Rs-T) ( 1.2 ). Limitations Of Use: Reblozyl Is Not Indicated For Use As A Substitute For Rbc Transfusions In Patients Who Require Immediate Correction Of Anemia ( 1.3 ). 1.1 Beta Thalassemia Reblozyl Is Indicated For The Treatment Of Anemia In Adult Patients With Beta Thalassemia Who Require Regular Red Blood Cell (Rbc) Transfusions. 1.2 Myelodysplastic Syndromes With Ring Sideroblasts Or Myelodysplastic/ Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis Associated Anemia Reblozyl Is Indicated For The Treatment Of Anemia Failing An Erythropoiesis Stimulating Agent And Requiring 2 Or More Red Blood Cell Units Over 8 Weeks In Adult Patients With Very Low- To Intermediate-Risk Myelodysplastic Syndromes With Ring Sideroblasts (Mds-Rs) Or With Myelodysplastic/myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis (Mds/mpn-Rs-T). 1.3 Limitations Of Use Reblozyl Is Not Indicated For Use As A Substitute For Rbc Transfusions In Patients Who Require Immediate Correction Of Anemia.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Luspatercept

Comments